Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Dexdor to sedate adult patients in the ICUs dexmedetomidine


Dexdor is a medicine that contains the active substance dexmedetomidine. It is available as a concentrate to be made up into a solution for infusion (drip into a vein).

 

Dexdor is used to sedate (calm or make sleepy) adult patients in hospital intensive care units. Dexdor is used to bring about a relatively light level of sedation in which the patient can still respond to verbal stimulation (corresponding to a score of between 0 and -3 on the Richmond Agitation-Sedation Scale).
The medicine can only be obtained with a prescription.
Dexdor is for hospital use only and should be given by a healthcare professional skilled in managing patients requiring intensive care.
Dexdor is given by infusion into a vein using a controlled infusion device. The doses are adjusted until the required level of sedation is attained. If adequate sedation is not achieved with the maximum dose, the patient should be switched to alternative sedative agent.
The active substance in Dexdor, dexmedetomidine, is a selective alpha-2 receptor agonist. It works by attaching to receptors in the brain called alpha-2 receptors and causes a reduction in the activity of the sympathetic nervous system which is involved in controlling people’s anxiety, arousal and sleep as well the blood pressure and heart rate. By reducing the activity of the sympathetic nervous system, dexmedetomidine helps to make patients calm or sleepy.
 
The effects of Dexdor were first tested in experimental models before being studied in humans.
 
Dexdor was compared with other sedative treatments (propofol or midazolam) in two main studies of 1,000 patients in intensive care units requiring sedation. The main measures of effectiveness were based on how well the medicines maintained the required sedation level and the time patients needed to spend on a mechanical ventilator.
Dexdor compared well with the comparator medicines in maintaining sedation. In one main study, 65% of patients given Dexdor maintained the required level of sedation compared with 65% of those receiving propofol. In the second study, 61% of patients given Dexdor maintained the required level of sedation compared with 57% of those receiving midazolam. The studies also showed a benefit of Dexdor in reducing the duration of mechanical ventilation.
 
The most frequently reported side effects with Dexdor are hypotension (low blood pressure), hypertension (high blood pressure) and bradycardia (slow heart rate), occurring in approximately 25%, 15% and 13% of patients respectively. 
 
Dexdor must not be used in people who are hypersensitive (allergic) to dexmedetomidine or any of the other ingredients. It must also not be used in patients with advanced heart block (a type of heart rhythm disorder), patients with uncontrolled hypotension and in patients with conditions such as stroke that affect the blood supply to the brain.
The CHMP noted that the studies showed that Dexdor compared well with other sedatives and will serve as an additional alternative medicine for achieving lighter levels of sedation in suitable patients. As dexmedetomidine has been in use in several countries as a sedative agent, its risks are well known and are considered to be manageable. The Committee therefore concluded that the benefits of Dexdor are greater than its risks and recommended that it be granted marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the European Union for Dexdor on 16 September 2011.
 

اضغط هنا للقراءة باللغة العربية

Prepared by: Laila Nour


Source :

European Medicine Agency 

 






Other Comments

Add a comment

You must sign in to use this servcie

Username:
Password:


facebook comments

Forgot your password


sign up

Consultants Corner

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details